KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationAmortization - GoodwillCost of RevenueEBIATGross ProfitLeasesLong-Term Debt IssuancesLong-Term Debt RepaymentsMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetShares IssuedShares OutstandingShares OutstandingShares RepurchasedShort-Term Debt issuancesShort-Term Debt repayments
Ratios

Pacira BioSciences (PCRX) EBIAT (2016 - 2026)

Pacira BioSciences has reported EBIAT over the past 17 years, most recently at $2.9 million for Q1 2026.

  • For Q1 2026, EBIAT fell 39.4% year-over-year to $2.9 million; the TTM value through Mar 2026 reached $5.1 million, up 104.95%, while the annual FY2025 figure was $7.0 million, 107.07% up from the prior year.
  • EBIAT for Q1 2026 was $2.9 million at Pacira BioSciences, up from $1.6 million in the prior quarter.
  • Over five years, EBIAT peaked at $25.8 million in Q2 2023 and troughed at -$143.5 million in Q3 2024.
  • A 5-year average of -$1.9 million and a median of $5.4 million in 2025 define the central range for EBIAT.
  • Biggest five-year swings in EBIAT: soared 1666.81% in 2023 and later crashed 1421.29% in 2024.
  • Year by year, EBIAT stood at -$10.1 million in 2022, then surged by 346.19% to $24.9 million in 2023, then tumbled by 35.5% to $16.0 million in 2024, then tumbled by 89.79% to $1.6 million in 2025, then surged by 78.13% to $2.9 million in 2026.
  • Business Quant data shows EBIAT for PCRX at $2.9 million in Q1 2026, $1.6 million in Q4 2025, and $5.4 million in Q3 2025.